Current Report Filing (8-k)
April 03 2023 - 9:21AM
Edgar (US Regulatory)
0001527728
false
0001527728
2023-03-30
2023-03-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 30, 2023
ENOCHIAN
BIOSCIENCES INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
000-54478 |
|
45-2559340 |
(State
or other jurisdiction |
|
(Commission
File Number) |
|
(I.R.S.
Employer |
of
incorporation) |
|
|
|
Identification
No.) |
1927
Paseo Rancho Castilla
Los
Angeles, CA 90032
(Address
of principal executive offices)
+1(305)
918-1980
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered
pursuant to Section 12(b) of the Act:
Title
of Each Class |
|
Trading
Symbol |
|
Name
of Each Exchange on Which Registered |
Common
Stock, par value $0.0001 per share |
|
ENOB |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
The information under Item 3.02
below is incorporated by reference into this Item 1.01.
Item 3.02 Unregistered
Sales of Equity Securities
On March 30, 2023, Enochian Biosciences
Inc., a Delaware corporation (the “Company”) closed a private placement (the
“Private Placement”) of (i) 2,178,070 shares (the “Shares”)
of its common stock, par value $0.0001 per share (“Common Stock”) and (ii)
1,089,036 common stock purchase warrants (the “Warrants” and together with
the Shares, the “Securities”), which represents 50% warrant coverage, at a
purchase price of $1.14 per share, for aggregate proceeds to the Company of $2,483,000. The Warrants are exercisable for five years from
the date of issuance and have an exercise price of $1.14 per share, payable in cash. The Private Placement was completed pursuant to Regulation
S promulgated under the Securities Act of 1933, as amended (“Regulation S”).
In connection with the Private
Placement, each investor executed a subscription agreement in the form of Exhibit 10.1 attached hereto. Each subscription agreement contains
customary representations and warranties of the Company and of each investor, including that all investors purchasing the Securities are
not “U.S. persons” as defined by Rule 902 of Regulation S. The Private Placement was made directly by the Company and no underwriter
or placement agent was engaged by the Company. The Company did not engage in general solicitation or advertising and did not offer the
Securities to the public in connection with the Private Placement.
The foregoing description of the
Subscription Agreement and Warrants does not purport to be complete, and is qualified in its entirety by reference to the form of subscription
agreement and form of Warrant attached hereto as Exhibits 10.1 and 4.1, which are incorporated by reference herein. The disclosure contained
in this Current Report on Form 8-K does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company,
and is made only as required under applicable rules for filing current reports with the Securities and Exchange Commission.
Item 8.01 Other Events.
On April
3, 2023, the Company published a letter to shareholders. A copy of the letter is furnished as Exhibit 99.1 to this Current Report on Form
8-K.
The information
included in this Item 8.01 and in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that Section or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ENOCHIAN BIOSCIENCES, INC. |
|
|
|
By: |
/s/ Luisa Puche |
|
|
Name: Luisa Puche
Title: Chief Financial Officer |
Date: April 3, 2023
3
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Apr 2023 to Apr 2024